Davis's Drug Guide
vandetanib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
**REMS Drug**
Pronunciation:
van-det-a-nib
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Caprelsa
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Vandetanib." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109604/all/vandetanib.
Vallerand AHA, Sanoski CAC, Quiring CC. Vandetanib. Davis's Drug Guide. F.A. Davis Company; 2023. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109604/all/vandetanib. Accessed April 18, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Vandetanib. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109604/all/vandetanib
Vallerand AHA, Sanoski CAC, Quiring CC. Vandetanib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2024 April 18]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109604/all/vandetanib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - vandetanib
ID - 109604
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109604/all/vandetanib
PB - F.A. Davis Company
ET - 18
DB - Pediatrics Central
DP - Unbound Medicine
ER -
